Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) EPS (Weighted Average and Diluted) (2021 - 2025)

Inmune Bio's EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at -$0.24 for Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 60.0% year-over-year to -$0.24; the TTM value through Sep 2025 reached -$2.13, up 2.74%, while the annual FY2024 figure was -$2.11, 26.35% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2025 was -$0.24 at Inmune Bio, up from -$1.06 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.24 in Q3 2025 and bottomed at -$1.06 in Q2 2025.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.43 (2025), against an average of -$0.48.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 60.0% in 2025 against a maximum downside of 112.0% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.56 in 2021, then surged by 43.78% to -$0.31 in 2022, then tumbled by 48.07% to -$0.47 in 2023, then grew by 14.16% to -$0.4 in 2024, then soared by 40.0% to -$0.24 in 2025.
  • Per Business Quant, the three most recent readings for INMB's EPS (Weighted Average and Diluted) are -$0.24 (Q3 2025), -$1.06 (Q2 2025), and -$0.43 (Q1 2025).